ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Ren, Shengxiang; Chen, Jianhua; Xu, Xingxiang; Jiang, Tao; Cheng, Ying; Chen, Gongyan; Pan, Yueyin; Fang, Yong; Wang, Qiming; Huang, Yunchao; Yao, Wenxiu; Wang, Rui; Li, Xingya; Zhang, Wei; Zhang, Yanjun; Hu, Sheng; Guo, Renhua; Shi, Jianhua; Wang, Zhiwu; Cao, Peiguo; Wang, Donglin; Fang, Jian; Luo, Hui; Geng, Yi; Xing, Chunyan; Lv, Dongqing; Zhang, Yiping; Yu, Junyan; Cang, Shundong; Yang, Zeyu; Shi, Wei; Zou, Jianjun; Zhou, Caicun*南昌大学; 哈尔滨医科大学; 浙江大学; 郑州大学; 同济大学; 重庆大学; 1
Journal of Thoracic Oncology2022-4DOI: 10.1016/j.jtho.2021.11.018
88被引20阅读
引用收藏
分享

摘要

Introduction: Camrelizumab, a humanized immunoglobulin G4-kappa monoclonal antibody against programmed cell death protein 1, has exhibited antitumor activity and tolerability across various tumors, including lung cancers. We conducted this double-blind, randomized phase 3 trial to investigate the efficacy and safety of camrelizumab or placebo plus chemotherapy as first-line treatment for patients with advanced squamous NSCLC. The predictive value of circulating tumor DNA (ctDNA) dynamics was also analyzed. @@@ Methods: CameL-sq, a double-blind, randomized phase 3 trial (NCT03668496), was conducted in 53 centers in the People's Republic of China. A total of 389 patients with stage IIIB-IV squamous NSCLC were randomized (1:1) to receive 4 to 6 cycles of carboplatin plus paclitaxel with camrelizumab or placebo (every 3 wk), followed by maintenance therapy with camrelizumab or placebo. Peripheral blood ctDNA samples were collected at baseline and the time after two cycles of treatment. @@@ Results: Of 389 eligible patients, 193 patients allocated camrelizumab plus chemotherapy and 196 patients allocated placebo plus chemotherapy were included in the efficacy and safety analysis. The results revealed significantly prolonged progression-free survival (median, 8.5 vs. 4.9 mo; p <0.0001) and overall survival (median, not reached vs. 14.5 mo; p <0.0001) with camrelizumab chemotherapy versus placebo-chemotherapy. No unexpected treatment immune-related adverse events were observed in both groups. Biomarker analysis revealed that ctDNA clearance after two cycles of treatment was independently associated with dramatically longer progression-free survival (p <0.0001) and overall survival (p <0.0001) in camrelizumab plus chemotherapy group. @@@ Conclusions: Our findings support camrelizumab plus chemotherapy as a first-line treatment option in advanced squamous NSCLC. On-treatment ctDNA dynamics exhibited the potency to predict the efficacy of camrelizumab plus chemotherapy.

学科与关键词

关键词
BiomarkerChemotherapyImmunotherapyLung squamous cell carcinomaPD-1
相关
加载中…
  • On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
    Jiang, Tao; Chen, Jianhua; Xu, Xingxiang; Cheng, Ying; Chen, Gongyan; Pan, Yueyin; Fang, Yong; Wang, Qiming; Huang, Yunchao; Yao, Wenxiu; Wang, Rui; Li, Xingya; Zhang, Wei; Zhang, Yanjun; Hu, Sheng; Guo, Renhua; Shi, Jianhua; Wang, Zhiwu; Cao, Peiguo; Wang, Donglin; Fang, Jian; Luo, Hui; Geng, Yi; Xing, Chunyan; Lv, Dongqing; Zhang, Yiping; Yu, Junyan; Cang, Shundong; Zhang, Yaxi; Zhang, Jiao; Yang, Zeyu; Shi, Wei; Zou, Jianjun; Zhou, Caicun*; Ren, Shengxiang*Molecular Cancer, 2022, 21(1): 4.被引 25
  • CamreliZumab Plus Carboplatin and PemetreXed as First-Line Treatment for Advanced NonsQuamous NSCLC: EXtended Follow-Up of CameL Phase 3 Trial
    Zhou, Caicun; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, LiZhu; Feng, Jifeng; Wang, Zhehai; Shu, YongQian; Shi, Jianhua; Hu, Yi; Wang, QiMing; Cheng, Ying; Wu, Fengying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng; Zhang, Yiping; Pan, Yueyin; Zhao, Jun; Wang, LiPing; Chang, Jianhua; Chen, Qun; Ren, Xiubao; Zhang, Wei; Fan, Yun; He, Zhiyong; Fang, Jian; Gu, Kangsheng; Dong, XiaoRong; Jin, Faguang; Gao, Hongjun; An, GuangyuJournal of Thoracic Oncology, 2023, 18(5): 628-639.被引 3
  • First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: Updated overall survival results from the phase III CameL-sq trial
    Zhou, C.; Cheng, Y.; Chen, J.; Xu, X.; Chen, G.; Pan, Y.; Fang, Y.; Wang, Q.; Huang, Y.; Yao, W.; Wang, R.; Li, X.; Zhang, W.; Zhang, Y.; Shi, J.; Cao, P.; Wang, D.; Lv, D.; Luo, H.; Yang, Z.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Thoracic Oncology
发表日期
2022-04
卷期
第 17 卷, 第 4 期
页码
544-557
DOI
10.1016/j.jtho.2021.11.018
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
Jiangsu Hengrui Pharmaceuticals; National Natural Science Foundation of People's Republic of China [81871865, 81874036, 81972167]; Backbone Program of Shanghai Pulmonary Hospital [FKGG1802]; Shanghai Pujiang Talent Plan [2019PJD048]; Shanghai Science and Technology Committee Foundation [19411950300]; Program of Shanghai Academic Research Leader [21XD1423200]; Shanghai Key disciplines of Respiratory [2017ZZ02012]

作者

  • R

    Ren, Shengxiang (第一作者)

    shanghai pulm hosp · tongji univ

  • C

    Chen, Jianhua

    1 · hunan canc hosp

查看全部 33 位作者收起作者
  • X

    Xu, Xingxiang

  • J

    Jiang, Tao

    shanghai pulm hosp · tongji univ

  • C

    Cheng, Ying

  • C

    Chen, Gongyan

    1 · harbin med univ

  • P

    Pan, Yueyin

    anhui prov hosp

  • F

    Fang, Yong

    zhejiang univ

  • W

    Wang, Qiming

  • H

    Huang, Yunchao

    kunming med univ

  • Y

    Yao, Wenxiu

  • W

    Wang, Rui

  • L

    Li, Xingya

    1 · zhengzhou univ

  • Z

    Zhang, Wei

    1 · nanchang univ

  • Z

    Zhang, Yanjun

  • H

    Hu, Sheng

    hubei canc hosp

  • G

    Guo, Renhua

  • S

    Shi, Jianhua

    2

  • W

    Wang, Zhiwu

    2

  • C

    Cao, Peiguo

  • W

    Wang, Donglin

    chongqing univ

  • F

    Fang, Jian

    2

  • L

    Luo, Hui

    2 · jiangxi canc hosp

  • G

    Geng, Yi

  • X

    Xing, Chunyan

    jinan cent hosp

  • L

    Lv, Dongqing

  • Z

    Zhang, Yiping

    zhejiang canc hosp

  • Y

    Yu, Junyan

    changzhi med coll

  • C

    Cang, Shundong

    henan prov peoples hosp

  • Y

    Yang, Zeyu

  • S

    Shi, Wei

  • Z

    Zou, Jianjun

  • Z

    Zhou, Caicun (通讯)

    shanghai pulm hosp · tongji univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417